CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled
Drug / intervention
Folate +1 moredrug
Likely dose
Folate 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00249288
NCT00249288Phase 4Completed
CompareCT.gov

Folate Supplementation in Schizophrenia

Massachusetts General Hospital·interventional·Posted Nov 7, 2005·Updated Apr 5, 2018

In Brief

A Phase 4 clinical trial evaluating Folate and Placebo for Schizophrenia. Completed, enrolled 46 participants across 1 site.

Detailed Summary

This study aims to examine factors potentially contributing to differences in blood folate, homocysteine or B12 levels between schizophrenia patients, to test the hypothesis that low folate is associated with negative symptoms, and to examine the efficacy of folate supplementation for reducing negative symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 7, 2005
Enrollment StartDec 1, 2003
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 20.7 years ago

Interventions

Folatedrug

Folic acid taken as 2, 1mg capsule daily for 12 weeks

Placebodrug

Placebo taken as 2, 1mg capsule daily for 12 weeks